iBio, Inc.

IBIO

US4510337086

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:10:00 2024-05-24 EDT			5-day change	1st Jan Change
2.19 ^USD	-1.13%		+10.61%	+59.85%

04-01	IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	CI
03-28	Top Premarket Gainers	MT

IBio, Inc. Announces Resignation of Robert L. Erwin as President

December 23, 2020 at 04:31 pm

On December 18, 2020, iBio, Inc. was advised by Mr. Robert L. Erwin of his intention to resign as President of the company, effective immediately. Mr. Erwin will retain his position as a member of the Company’s Scientific Advisory Board.

Latest news about iBio, Inc.

IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	03-31	CI
Top Premarket Gainers	03-28	MT
Top Midday Gainers	03-27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	03-27	MT
Transcript : IBio, Inc. - Special Call	03-27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	03-27	MT
Top Premarket Gainers	03-27	MT
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	03-27	CI
IBio, Inc. announced that it has received $14 million in funding	03-25	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	02-26	DJ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	02-24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-09	CI
Top Midday Decliners	12-05	MT
Top Premarket Decliners	12-05	MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	11-28	DJ
IBio Board Approves 20-to-1 Reverse Split of Common Stock Effective Nov. 29; Shares Sink 11% After Hours	11-27	MT
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx	11-01	CI
North American Morning Briefing : Stock Futures, -2-	23-10-02	DJ
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ
IBio Unit, Woodforest National Bank Amend Credit Agreement	23-09-21	MT
IBio, Inc. Reports Triple Milestone in Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development	23-08-14	CI
IBio, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC	23-08-03	CI
IBio Names Martin Brenner Chief Executive; Felipe Duran Appointed as Finance Chief	23-06-27	MT

Chart iBio, Inc.

Duration

Period

More charts

Company Profile

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Sector

Pharmaceuticals

Calendar

2024-09-23 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
IBIO, INC.	+59.85%	19.07M
ELI LILLY AND COMPANY	+38.51%	728B
NOVO NORDISK A/S	+33.05%	603B
JOHNSON & JOHNSON	-6.23%	360B
MERCK & CO., INC.	+18.78%	332B
ABBVIE INC.	+1.35%	279B
ASTRAZENECA PLC	+16.00%	244B
NOVARTIS AG	+8.09%	207B
ROCHE HOLDING AG	-5.77%	205B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

iBio, Inc.

Equities

IBIO

US4510337086

Pharmaceuticals

IBio, Inc. Announces Resignation of Robert L. Erwin as President

Latest news about iBio, Inc.

Chart iBio, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals